Zoetis Inc. — 2018 Form 10-K Summary
Business context and reporting period
Zoetis develops, manufactures and sells animal health medicines, vaccines and diagnostics for livestock and companion animals. This annual report covers the fiscal year ended December 31, 2018; quarterly figures below include the fourth quarter. The company reports U.S. and International segments and sells products in more than 100 countries.
Financial performance
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $5.825 billion | $5.307 billion | +10% |
| GAAP net income attributable to Zoetis | $1.428 billion | $864 million | +65% |
| Diluted EPS | $2.93 | $1.75 | +67% |
| Adjusted net income (non-GAAP) | $1.525 billion | $1.185 billion | +29% |
| Adjusted diluted EPS (non-GAAP) | $3.13 | $2.40 | +30% |
| Operating cash flow | $1.790 billion | $1.346 billion | +33% |
| Capital expenditures | $338 million | $224 million | +$114 million |
| Cash and cash equivalents, year-end | $1.602 billion | $1.564 billion | +$38 million |
| Long-term debt, year-end | $6.443 billion | $4.953 billion | +$1.490 billion |
Cost of sales was 33% of revenue, implying an approximate 67% gross margin, broadly steady with 2017. GAAP net margin rose to about 25% from 16%; the increase was substantially influenced by lower taxes. The effective tax rate was 15.7%, versus 43.5% in 2017, which included a provisional Tax Act charge. Working capital was $3.176 billion and the current ratio was 3.60:1 at year-end.
Fourth-quarter revenue was $1.564 billion, up about 7% from $1.460 billion a year earlier. Net income attributable to Zoetis was $345 million versus $81 million, and diluted EPS was $0.71 versus $0.16; the prior-year quarter included a provisional Tax Act charge. Fourth-quarter costs and expenses reflect seasonal trends.
Material changes versus prior periods
- Revenue growth was driven by approximately 3% price growth, 3% volume growth in in-line products, about 2% from Abaxis, and about 2% from new products. Foreign exchange had no net impact on reported annual revenue growth.
- Companion-animal revenue increased 17% to $2.613 billion, led by dermatology products, new products and Abaxis. Livestock revenue increased 4% to $3.154 billion.
- U.S. revenue rose 10% to $2.877 billion; International revenue rose 9% to $2.890 billion. Segment earnings increased 11% and 13%, respectively.
- Zoetis acquired veterinary diagnostics provider Abaxis on July 31, 2018, for approximately $1.962 billion. Abaxis contributed $107 million revenue after acquisition; acquisition-related costs, purchase-accounting charges and acquired-asset amortization affected reported results.
- Research and development expense rose 13% to $432 million. Selling, general and administrative expense rose 11% to $1.484 billion, partly reflecting Abaxis and higher compensation and professional-services costs.
- Operating cash flow improved, attributed primarily to higher income, timing of receipts and payments, and lower inventory levels. Investing cash outflow increased to $2.259 billion, primarily due to Abaxis and other acquisitions and capital spending.
Outlook, commentary, risks and unusual items
- The filing refers to 2019 financial guidance but the provided filing text does not include clear numerical guidance values.
- Management cited continued product innovation, lifecycle development, international growth, diagnostics, and digital and data solutions as strategic priorities.
- Key risks include reliance on leading products (the top four accounted for about 25% of 2018 revenue), patent expirations and generic competition, product safety or supply disruptions, regulatory constraints on livestock antibacterials, animal disease outbreaks, customer consolidation, foreign exchange, and acquisition integration.
- Antibacterial products for livestock generated approximately $1.3 billion of 2018 revenue; further restrictions or consumer preference shifts could affect demand. The filing also identifies weather, natural-resource availability, tariffs, Brexit, cyber and privacy risks, and environmental liabilities.
- Debt totaled approximately $6.4 billion. The company issued $1.5 billion of senior notes in 2018, including $300 million of floating-rate notes; interest expense increased 18% to $206 million. The $1.0 billion revolving facility was undrawn and the company reported compliance with its covenants.
- Significant items included a $42 million gain on divestiture of agribusiness products, an $18 million gain related to a China manufacturing-site relocation, and a $45 million tax benefit from a Tax Act measurement-period adjustment. The 2018 effective tax rate also reflects the U.S. corporate rate reduction and other tax items.
- Management considered the likelihood of a material adverse effect from pending proceedings remote, but stated that unfavorable outcomes could affect results or cash flows. A European Union tax ruling issued after year-end was under review; no related potential benefit was recorded in 2018.
Important facts for investors to verify
- Review the full 2019 guidance and subsequent disclosures; numerical guidance is not clear in the supplied text.
- Assess the durability of growth in Apoquel, Draxxin, ceftiofur and Revolution/Stronghold, and monitor disclosed patent-expiry and generic-entry timelines.
- Track Abaxis integration, realized synergies, recurring operating costs, and the acquisition’s effect on returns and leverage.
- Reconcile GAAP and adjusted earnings, particularly the effects of tax benefits, purchase accounting and acquisition-related exclusions.
- Monitor debt service, floating-rate exposure, liquidity and capital allocation, including the additional $2.0 billion share-repurchase authorization and dividends.
- Follow regulatory developments on livestock antibiotics, product quality and supply, litigation and environmental contingencies, and material foreign-exchange or trade-policy changes.